Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Director Sells 3,600 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,600 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the completion of the sale, the director now owns 21,641 shares in the company, valued at approximately $1,022,753.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded down $2.77 during trading on Wednesday, reaching $42.49. The stock had a trading volume of 962,106 shares, compared to its average volume of 941,048. The business has a fifty day moving average price of $43.92 and a 200-day moving average price of $45.93. The stock has a market cap of $2.49 billion, a PE ratio of -11.12 and a beta of 1.78. Twist Bioscience Co. has a 1-year low of $18.59 and a 1-year high of $60.90.

Analysts Set New Price Targets

A number of analysts have weighed in on TWST shares. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Evercore ISI increased their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of the company. Signaturefd LLC raised its stake in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after buying an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.